Research Article
Alendronate Can Improve Bone Alterations in Experimental Diabetes by Preventing Antiosteogenic, Antichondrogenic, and Proadipocytic Effects of AGEs on Bone Marrow Progenitor Cells
Figure 1
Effect of AGEs and/or alendronate on BMPC osteoblastic differentiation. BMPC were obtained from nondiabetic untreated animals and cultured in an osteogenic medium with the indicated concentrations of control BSA or AGEs-BSA (200 mg/mL if not indicated), with or without different doses of alendronate (as indicated, or 10−8 M if not indicated), for either 15 days (a–d and f) or 21 days (e). Type 1 collagen production (a and c), alkaline phosphatase activity (b and d), extracellular nodules of mineralization (e), and expression of Runx2 by Western blot (f) were evaluated. Results are expressed as the mean ± SEM. (a and b) versus 50 mg/mL control BSA; (c–f) versus control BSA, versus AGEs-BSA.
| (a) |
| (b) |
| (c) |
| (d) |
| (e) |
| (f) |